Highlights of clinical and laboratory parameters among severe COVID-19 patients treated with tocilizumab: a retrospective observational study

Highlights of clinical and laboratory parameters among severe COVID-19 patients treated with tocilizumab: a retrospective observational study

ABSTRACT BACKGROUND: Coronavirus disease 2019 (COVID-19) can cause cytokine release syndrome (CRS), which leads to high mortality rates. Tocilizumab suppresses CRS by blocking the signal transduction of interleukin-6 (IL-6). OBJECTIVE: To evaluate the clinical and laboratory parameters associated...

Full description

Bibliographic Details
Main Authors: Melahat Uzel Şener, Tuğba Çiçek, Ayperi Öztürk
Format: Article
Language:English
Published: Associação Paulista de Medicina 2022-07-01
Series:São Paulo Medical Journal
Subjects:
COVID-19
Cytokine release syndrome
Mortality
Interleukins
Neutrophils
Lymphocytes
Tocilizumab supplementary concept
Hyperinflammation
SARS coronavirus 2
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802022005017203&tlng=en

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802022005017203&tlng=en

Similar Items